In response to the COVID-19 global pandemic, the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), has expanded funding opportunities up to $749K to establish public-private partnerships with diagnostic providers for the purpose of developing solutions to mitigate the public health impact of the coronavirus disease 2019 (COVID-19). A large and important part is the immediate need for diagnostic tests that can quickly and accurately diagnose COVID-19 and mitigate the spread of the disease. HHS is focused on setting examples of the commitment to make diagnostic available through public-private partnerships with industry. “Our partnerships with industry and with counterparts from across the federal government have brought products over the regulatory finish line to protect the American people, strengthen health security and, ultimately, save lives,” stated BARDA Director Rick A. Bright, Ph.D., in a recent blog.
The Broad Agency Announcement (BAA) funding is part of a set aside for entities that meet any of the U.S. Department of Health and Human Services (HHS) Development Opportunity Objectives:
The funding award is a fixed cost contract set aside, meaning the funding has already been approved and earmarked for immediate distribution to qualifying partners. In most cases BARDA can make awards available in as few as 30 days through their expedited review process — ASPR's Biomedical Advanced Research and Development Authority streamlined selection process — called an easy broad agency announcement (EZ-BAA). More information and registration for the ASPR can be found at EZ BAA at the following HHS partner portal DRIVe.